Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
4.2
Journals
Molecules
Special Issues
Novel Strategies for the Prevention and Treatment of Cardiovascular Diseases:...
molecules-logo
Submit to Molecules Review for Molecules Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Novel Strategies for the Prevention and Treatment of Cardiovascular Diseases: New Horizons from Pharmaceuticals to Nutraceuticals

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 4658

Special Issue Editors

Dr. Maria Alessandra Gammone

E-Mail
Guest Editor
Department of Medical Oral and Biotechnological Sciences, University of Chieti-Pescara, Chieti, Italy
Interests: nutrition; bioactive compounds; nutraceuticals; cardiovascular diseases; metabolic diseases
Prof. Dr. Nicolantonio D'orazio

E-Mail Website
Guest Editor
Department of Biomedical Sciences, University of Chieti-Pescara, Chieti, Italy
Interests: obesity; diabetes; nutrition; nu traceuticals; cardiometabolic diseases
Dr. Maria Giulia Gagliardi

E-Mail Website
Guest Editor
Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesù Children's Hospital, Rome, Italy
Interests: interventional cardiology; congenital heart disease; prevention; myocarditis

Special Issue Information

Dear Colleagues,

Cardiovascular diseases have gained increasing attention because of their high prevalence and mortality worldwide.

Substantial progress has been made in developing therapies that address the risk of cardiovascular disease.

Pharmaceutical agents play a major role in the prevention of atherosclerosis and its consequences: heart attack, stroke, and heart failure. Additionally, novel device-based therapies are contributing to the decline in cardiac morbidity and mortality. A concrete hope exists that lifestyle changes, early risk factor screening, nutraceuticals, and more efficacious pharmaceuticals will reduce cardiovascular risk in the future.

In this Special Issue, we are interested in original and review articles that assess both novel strategies of prevention and clinical outcomes as a consequence of various treatment advances in this area, thus discussing future research directions. This issue should be of interest to a wide range of clinicians that encounter cardiovascular diseases, especially those who treat comorbidities.

Dr. Maria Alessandra Gammone
Prof. Dr. Nicolantonio D'orazio
Dr. Maria Giulia Gagliardi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular diseases
  • overweight
  • obesity
  • inflammation
  • hypertension
  • dyslipidemia
  • lifestyle
  • pharmaceuticals
  • nutraceuticals
  • nutrition
  • diabetes
  • prevention
  • treatment
  • cardiovascular risk

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 1295 KiB  
Article
The Anti-Aggregative Potential of Resolvin E1 on Human Platelets
by Patrycja Szymańska, Bogusława Luzak, Katarzyna Miłowska and Jacek Golański
Molecules 2023, 28(14), 5323; https://doi.org/10.3390/molecules28145323 - 11 Jul 2023
Cited by 1 | Viewed by 1103
Abstract
Resolvin E1 is a metabolite of eicosapentaenoic acid (EPA) which is one of the omega-3 polyunsaturated fatty acids (omega-3 PUFAs). The antiplatelet properties of omega-3 PUFAs are well known, but the effect of resolvin E1 on platelets via the collagen receptors is extremely [...] Read more.
Resolvin E1 is a metabolite of eicosapentaenoic acid (EPA) which is one of the omega-3 polyunsaturated fatty acids (omega-3 PUFAs). The antiplatelet properties of omega-3 PUFAs are well known, but the effect of resolvin E1 on platelets via the collagen receptors is extremely poorly reported. We investigated the effect of resolvin E1 on collagen-induced platelet aggregation, activation, and reactivity, and also platelet membrane fluidity. The ultimate and statistically significant results showed that resolvin E1 may inhibit platelet reactivity due to the reduction of collagen-induced platelet aggregation in platelet-rich plasma and isolated platelets, but not in whole blood. Also, resolvin E1 significantly reduced P-selectin exposure on collagen-stimulated platelets. Moreover, we demonstrated that resolvin E1 can maintain platelet membrane structure (without increasing membrane fluidity). The association between platelet reactivity and membrane fluidity, including resolvin E1 and collagen receptors requires further research. However, the goal of this study was to shed light on the molecular mechanisms behind the anti-aggregative effects of resolvin E1 on platelets, which are still not fully clarified. We also indicate an innovative research direction focused on further analysis and then use of omega-3 PUFAs metabolites as antiplatelet compounds for future applications in the treatment and prevention of cardiovascular diseases. Full article
(This article belongs to the Special Issue Novel Strategies for the Prevention and Treatment of Cardiovascular Diseases: New Horizons from Pharmaceuticals to Nutraceuticals)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 1458 KiB  
Review
Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
by Collin Vandemark, Jimmy Nguyen and Zhi-Qing Zhao
Molecules 2023, 28(3), 1369; https://doi.org/10.3390/molecules28031369 - 1 Feb 2023
Cited by 7 | Viewed by 2944
Abstract
Angiotensin II (Ang II), a peptide hormone generated as part of the renin–angiotensin system, has been implicated in the pathophysiology of many cardiovascular diseases such as peripheral artery disease, heart failure, hypertension, coronary artery disease and other conditions. Liraglutide, known as an incretin [...] Read more.
Angiotensin II (Ang II), a peptide hormone generated as part of the renin–angiotensin system, has been implicated in the pathophysiology of many cardiovascular diseases such as peripheral artery disease, heart failure, hypertension, coronary artery disease and other conditions. Liraglutide, known as an incretin mimetic, is one of the glucagon-like peptide-1 (GLP-1) receptor agonists, and has been proven to be effective in the treatment of cardiovascular disorders beyond adequate glycemic control. The objective of this review is to compile our recent experimental outcomes-based studies, and provide an overview the cardiovascular protection from liraglutide against Ang II- and pressure overload-mediated deleterious effects on the heart. In particular, the mechanisms of action underlying the inhibition of oxidative stress, vascular endothelial dysfunction, hypertension, cardiac fibrosis, left ventricular hypertrophy and heart failure with liraglutide are addressed. Thus, we support the notion that liraglutide continues to be a useful add-on therapy for the management of cardiovascular diseases. Full article
(This article belongs to the Special Issue Novel Strategies for the Prevention and Treatment of Cardiovascular Diseases: New Horizons from Pharmaceuticals to Nutraceuticals)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop